ONCO
Onconetix, Inc.
There isn't enough reported data to score ONCO yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ONCO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ONCO's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ONCO PE Valuation
ONCO has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ONCO Forward outlook
There aren't enough analyst estimates for ONCO to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ONCO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$766,680.00 | +$3,828,845.00 |
| Q2 2025 | -$888,080.00 | +$4,109,920.00 |
| Q1 2025 | -$1,973,700.00 | +$2,293,300.00 |
| Q4 2024 | -$2,801,175.00 | +$921,825.00 |
| Q3 2024 | -$4,595,525.00 | -$2,923,041.56 |
| Q2 2024 | -$4,998,000.00 | -$3,393,516.56 |
| Q1 2024 | -$4,267,000.00 | -$2,407,516.56 |
| Q4 2023 | -$3,723,000.00 | -$1,853,000.00 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 117% for ONCO versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ONCO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $17.1K | -84% |
| Q1 2026 | $21.5K | -79% |
| Q4 2025 | $303.6K | -57% |
| Q3 2025 | $303.7K | -25% |
| Q2 2025 | $106.5K | -85% |
| Q1 2025 | $101.6K | -75% |
ONCO's revenue has slid since its 2024 peak: $17,120 last quarter, down 84% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -15951% | -14134 points |
| Q1 2026 | -47657% | -35288 points |
| Q4 2025 | -422% | +3672 points |
| Q3 2025 | -681% | -31 points |
| Q2 2025 | -1817% | +114 points |
| Q1 2025 | -12369% | -9599 points |
| Q4 2024 | -4094% | N/A |
| Q3 2024 | -650% | N/A |
ONCO's operating margin was −15951% last quarter, down 14133 points from the same quarter a year ago, near the bottom of its range since 2024.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ONCO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ONCO on profitability, with a higher operating margin.
ONCO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$921.5K | +$3.4M |
| Q3 2024 | -$1.1M | +$1.9M |
| Q2 2024 | -$3.2M | -$1.4M |
| Q1 2024 | -$5.2M | -$788.7K |
| Q4 2023 | -$4.3M | -$1.5M |
| Q3 2023 | -$3M | -$1.2M |
| Q2 2023 | -$1.8M | +$1.4M |
| Q1 2023 | -$4.4M | -$3.6M |
ONCO has the stronger cash trend. Its trailing FCF is up 49% versus its history, compared with UNH at up 5.2%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ONCO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3468% | +218K shares |
| 1 year | +52301% | +224K shares |
| 3 years | +3203857% | +224K shares |
ONCO has 224,277 diluted shares, up 52301% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | $25,527 |
| Q1 2023 | $33,454 |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ONCO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ONCO Net Leverage
ONCO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ONCO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.5 | Oversold |
| Stochastic | 17.9 | Oversold |
ONCO's weekly RSI is 29 (oversold) and its Stochastic is 18 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ONCO PE vs Healthcare Sector
ONCO has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ONCO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.05 | 50% below |
| 20 week MA | $7.26 | 58% below |
| 50 week MA | $229.4 | 99% below |
| 100 week MA | $3,385.0 | 100% below |
| 200 week MA | $414,179.2 | 100% below |
ONCO is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ONCO on trend strength, trading above more of its moving averages.
ONCO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $97,580,000.0 | $1,751,000.0 | -98% |
| 2023 | $1,751,000.0 | $336,600.0 | -81% |
| 2024 | $336,600.0 | $16,365.1 | -95% |
| 2025 | $16,365.1 | $715.0 | -96% |
| 2026 YTD | $715.0 | $3.03 | -100% |
ONCO has finished every year since 2022 lower, and it's down 100% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ONCO on returns for 2026, with the stronger performance.